Navidea Biopharmaceuticals, Inc. announced the company and Capital Royalty Partners II, L.P. and other related entities have entered into a binding settlement agreement and mutual release settling all ongoing litigation between the parties. To provide the funding necessary for the CRG settlement, Navidea entered into a Loan and Securities Exchange agreement pursuant to which John Scott, Jr., Vice Chair of the Board, loaned Navidea Biopharma $750 thousand with a maturity date of April 10, 2025.
Navidea and CRG have been engaged in ongoing litigation since 2016. On August 30, 2022, a judgment was entered against Navidea. As of September 30, 2023, the contingent liability for the judgment and accrued interest was $2.71 million.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
March 28, 2025 11:47 ET Revised growth data for the U.S. economy was the highlight of the week that also had some key reports from other major economies. The fourth quarter growth figures underwent revision in the latest report. Elsewhere, a survey revealed the U.S. consumers’ view on the economy. In mainland Europe, a survey in Germany revealed the business leaders’ assessment of the current situation and their hopes for the future. In other news, inflation data from the U.K. and Australia were in focus.